Novartis has agreed to pay privately-owned Enanta Pharmaceuticals Inc $34 million upfront, plus potential milestones of $406 million, for exclusive rights to a compound to treat hepatitis C. The compound is poised to enter clinical development. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
